- Home
- LCTX vs TDF Comparison
LCTX vs TDF Comparison
Compare LCTX & TDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TDF
- Stock Information
- Founded
- LCTX 1990
- TDF 1994
- Country
- LCTX United States
- TDF Singapore
- Employees
- LCTX N/A
- TDF N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TDF Finance/Investors Services
- Sector
- LCTX Health Care
- TDF Finance
- Exchange
- LCTX Nasdaq
- TDF Nasdaq
- Market Cap
- LCTX 274.0M
- TDF 244.7M
- IPO Year
- LCTX N/A
- TDF N/A
- Fundamental
- Price
- LCTX $1.73
- TDF $11.57
- Analyst Decision
- LCTX Strong Buy
- TDF
- Analyst Count
- LCTX 4
- TDF 0
- Target Price
- LCTX $4.25
- TDF N/A
- AVG Volume (30 Days)
- LCTX 1.8M
- TDF 79.2K
- Earning Date
- LCTX 11-13-2025
- TDF 01-01-0001
- Dividend Yield
- LCTX N/A
- TDF N/A
- EPS Growth
- LCTX N/A
- TDF N/A
- EPS
- LCTX N/A
- TDF N/A
- Revenue
- LCTX $10,914,000.00
- TDF N/A
- Revenue This Year
- LCTX N/A
- TDF N/A
- Revenue Next Year
- LCTX $176.00
- TDF N/A
- P/E Ratio
- LCTX N/A
- TDF N/A
- Revenue Growth
- LCTX 76.43
- TDF N/A
- 52 Week Low
- LCTX $0.37
- TDF $7.15
- 52 Week High
- LCTX $1.85
- TDF $10.62
- Technical
- Relative Strength Index (RSI)
- LCTX 62.37
- TDF 55.88
- Support Level
- LCTX $1.53
- TDF $11.25
- Resistance Level
- LCTX $1.77
- TDF $11.48
- Average True Range (ATR)
- LCTX 0.10
- TDF 0.30
- MACD
- LCTX -0.01
- TDF -0.01
- Stochastic Oscillator
- LCTX 74.94
- TDF 59.70
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.